Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell has opted to end development of ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...